Jennifer Madonia

Clinical evaluation of [18F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer’s disease

Mark E. Schmidt, D. Moechars, H. Kolb, 2020, European Journal of Nuclear Medicine and Molecular Imaging.

Assessment of F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy

K. Bötzel, A. Drzezga, M. Schroeter, 2020 .

Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double‐blind, randomized, placebo‐controlled, dose‐ranging trial

V. Coric, Jennifer Madonia, R. Croop, 2022, Headache.

P‐Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy Subjects

V. Coric, R. Bertz, Jennifer Madonia, 2022, Clinical pharmacology in drug development.

Human Milk and Plasma Pharmacokinetics of Single-Dose Rimegepant 75 mg in Healthy Lactating Women

V. Coric, R. Bertz, Jennifer Madonia, 2022, Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine.

Tau PET imaging with 18F-PI-2620 in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans Study

J. Seibyl, S. de Santi, K. Marek, 2019, The Journal of Nuclear Medicine.

Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy

F. Jessen, K. Bötzel, J. Seibyl, 2020, JAMA neurology.

Binding characteristics of [18F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET

Özgür A. Onur, F. Jessen, K. Bötzel, 2021, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

18F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear Palsy

J. Seibyl, M. Schroeter, K. Hoffmann, 2022, The Journal of Nuclear Medicine.

Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury

Özgür A. Onur, F. Jessen, K. Bötzel, 2020, European Journal of Nuclear Medicine and Molecular Imaging.

FIRST-IN-HUMAN PET STUDIES WITH THE NEXT GENERATION TAU AGENT 18-F PI-2620 IN ALZHEIMER’S DISEASE, PROGRESSIVE SUPRANUCLEAR PALSY, AND CONTROLS

J. Seibyl, K. Marek, L. Dinkelborg, 2017, Alzheimer's & Dementia.

Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial

P. Goadsby, V. Coric, Jennifer Madonia, 2023, The Lancet Neurology.

Evaluation of Dosimetry, Quantitative Methods, and Test–Retest Variability of 18F-PI-2620 PET for the Assessment of Tau Deposits in the Human Brain

J. Seibyl, K. Marek, L. Dinkelborg, 2019, The Journal of Nuclear Medicine.